

UK NEQAS


International Quality Expertise



2022-2023

Services Available List

EQA programme directory for all UK NEQAS Centres



www.ukneqas.org.uk



Who are UK NEQAS?

United Kingdom National External Quality Assessment Service (UK NEQAS) is the **world leading** provider of clinical laboratory External Quality Assessment (EQA)/Proficiency Testing (PT) programmes. The EQA/PT programmes provided by UK NEQAS are designed and operated by highly experienced organisers and scientists, wholly committed to improving the quality of testing in healthcare laboratories for the benefit of patients worldwide.

To ensure the provision of high quality EQA/PT and delivery of appropriate scientific support in each specialist area of clinical laboratory testing, each UK NEQAS service is operated from a dedicated expert centre. These 20 centres are in 11 cities around the UK and together they form the UK NEQAS Consortium, a not-for-profit company limited by guarantee and a UK Registered Charity (no: 1044013). Each UK NEQAS member centre operates on a strict not for profit basis, has no commercial interests and is **accredited to ISO 17043:2010**.

“The EQA/PT programmes provided by UK NEQAS are designed and operated by highly experienced organisers and scientists”

In addition to delivering over 500 different EQA/PT programmes, UK NEQAS also operates PrepQ, a dedicated Pre- and Post- Analytical Quality Monitoring service which has been designed to allow participating laboratories to monitor their pre and post analytical issues to support the requirements of ISO 15189.

To supplement the UK NEQAS EQA/PT programmes and ensure that any findings identifying factors associated with good or poor performance are shared with laboratories, we regularly publish in peer reviewed journals, host scientific meetings and run educational webinars.

At UK NEQAS we believe that this approach ensures the best possible quality service is provided to clinical laboratories, and that this supports the continual improvement of healthcare service delivery worldwide. When selecting an EQA/PT service, it is clear to see why thousands of laboratories globally have chosen to use UK NEQAS.

Thank you for selecting and supporting UK NEQAS.

Liam Whitby
President, UK NEQAS

Our Mission

IMPROVING GLOBAL
DIAGNOSTIC TESTING FOR
THE BENEFIT OF PATIENTS THROUGH
QUALITY ASSESSMENT AND EDUCATION

Contents

Cellular Pathology

Pages 4 - 5

Cellular Pathology Technique
Head & Neck Pathology
Immunocytochemistry & In-Situ Hybridisation
Neuropathology

Clinical Chemistry

Pages 5 - 7

Birmingham Quality
Cardiac Markers
Edinburgh Peptide Hormones
Guildford Peptides
Trace Elements

Genomics

Pages 7 - 9

GenQA

Haematology

Pages 10 - 12

Blood Coagulation
Blood Transfusion Laboratory Practice
Haematology
Leucocyte Immunophenotyping

Immunology

Pages 12 - 13

Histocompatibility & Immunogenetics
Immunology, Immunochemistry & Allergy

Medical Microbiology

Page 14

Microbiology
Parasitology

Reproductive Science

Page 15

Reproductive Science

Point of Care Testing

Page 16

PrepQ

Page 17

Programme Index

Pages 18-27

Participating Countries

Pages 28-29

UK NEQAS Centre Contacts

Back page

Cellular Pathology

Cellular Pathology Technique	
Tel:	+44 (0) 191 816 1030
Email:	cpt@ukneqas.org.uk
Legal Entity:	LabXCell LTD
Services Available	
Slide Based Schemes	
Tissue Diagnostics	
Specialist Techniques	
Neuropathology	
Frozen Section (Companion Scheme to Specialist Techniques and Neuropathology)	
Mega Block (Companion Scheme to Specialist Techniques and Neuropathology)	
Muscle Histochemistry	
Renal Biopsy Pathology	
Diagnostic Cytopathology	
Diagnostic Cytopathology Cell Block (Pilot)	
Bone Marrow Trepine Biopsy (BMT)	
Mohs' Procedure	
Web Based Schemes	
Transmission Electron Microscopy (TEM)	
Direct Immunofluorescence (DIF)	
Digital Pathology (Pilot)	
Digital Interpretive Web Based Schemes	
Digital Interpretative Diagnostic Cytopathology	
Digital Diagnostic Ultrastructural Pathology (Pilot)	
Digital Interpretative Synovial Fluid Crystals (Pilot)	



Head and Neck Pathology	
Tel:	+44 (0) 121 371 5723
Email:	neckpath@ukneqas.org.uk
Legal Entity:	British Society for Oral & Maxillofacial
Services Available	
Head and Neck Pathology (Oral, ENT & Combined)*	

Immunocytochemistry and In-Situ Hybridisation	
Tel:	+44 (0) 208 187 9174
Email:	info@ukneqasiccish.org
Legal Entity:	External Quality Assessment Services for Cancer Diagnostics CIC
Services Available	
Immunocytochemistry	
Alimentary Tract Pathology (GIST)	
Breast Pathology (HER2 IHC)	
Breast Pathology (Hormonal Receptors ER & PR)	
Breast Pathology (Hormonal Receptors ER only)	
Cytopathology	
Gastric HER2 IHC	
General Pathology	
Lymphoid Pathology	
Mismatch Repair (MMR) Proteins	
Neuropathology	
Non-Small Cell Lung Cancer (NSCLC) ALK IHC	
Non-Small Cell Lung Cancer (NSCLC) PD-L1 IHC (Pilot)	
Non-Small Cell Lung Cancer (NSCLC) ROS1 IHC (Pilot)	
Triple Negative Breast Cancer (TNBC) PD-L1 IHC (Pilot)	

* not included in the current scope of accreditation

Cellular Pathology

Immunocytochemistry and In-Situ Hybridisation	
Services Available	
Immunocytochemistry (continued)	
Ki-67 in Breast Cancer (Pilot)	
p16 in Head & Neck Pathology (Pilot)	
In-Situ Hybridisation	
Breast HER2 ISH (Interpretive and Technical)	
Non-Small Cell Lung Cancer (NSCLC) ALK ISH (Pilot)	
Non-Small Cell Lung Cancer (NSCLC) ROS1 FISH (Pilot)	
High-risk HPV in Head & Neck Pathology (Pilot)	

Neuropathology	
Tel:	+44 (0) 1865 234 904
Email:	neuropath@ukneqas.org.uk
Legal Entity:	Oxford University Hospitals NHS Foundation Trust
Services Available	
Neuropathology Interpretative EQA Scheme*	

Clinical Chemistry

Birmingham Quality	
Tel:	+44 (0) 121 414 7300
Email:	birminghamquality@uhb.nhs.uk
Legal Entity:	University Hospitals Birmingham NHS Foundation Trust
Services Available	
ACE *	
Acute and Chronic Kidney Disease (Creatinine, Cystatin C, eGFR and AKI)	
Antibiotic Assays	
Antifungal Assays	
Bile Acids *	
Clinical Chemistry	
Erythropoietin	

Clinical Chemistry

Birmingham Quality
Services Available
Faecal Haemoglobin
Faecal Markers
Faecal Pancreatic Elastase
Fluids
Fructosamine
Glycated Haemoglobins
Haematinics
Holo-transcobalamin
Immunosuppressants
Interpretative Comments in Clinical Chemistry
Intrinsic Factor Antibodies
Lipid Investigations
MK-4 at endogenous concentrations in human serum
MK-7 at endogenous concentrations in human serum
Newborn Screening
Paediatric Bilirubin
Quantitative Amino Acids
Serum Indices (HIL)
Specific Proteins
Steroid Hormones
Sweat Testing
Thyroglobulin
Thyroid Hormones
Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)
Urinary Catecholamines & Metabolites
Urine Chemistries
Urine Dipsticks
Vitamin Assays (Carotene, Vitamin A & E)
Vitamin D
Vitamin K1, 2, 3-epoxide at endogenous concentrations in human serum
Vitamin K1 at endogenous concentrations in human serum

* not included in the current scope of accreditation

Clinical Chemistry

Cardiac Markers	
Tel:	+44 (0) 141 440 2888
Email:	info@ukneqas-cm.org.uk
Legal Entity:	NHS Greater Glasgow & Clyde
Services Available	
Cardiac Markers Schemes (Laboratory)	
hs Cardiac Troponin I, hs Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	
B-Type Natriuretic Peptide (BNP)	
Cardiac Markers Schemes (Point of Care)	
Cardiac Troponin I, Cardiac Troponin T, CKMB, Myoglobin, BNP *, NT-proBNP	
High Sensitivity Cardiac Troponin I (Pilot)	

Edinburgh Peptide Hormones	
Tel:	+44 (0) 131 242 6885
Email:	ukneqas@ed.ac.uk
Legal Entity:	NHS Lothian
Services Available	
Maternal Serum Screening	
1st Trimester (Down's syndrome and Trisomies T13 and T18)	
1st Trimester (Down's syndrome using dried blood spots) (Pilot)	
2nd Trimester (Down's syndrome)	
2nd Trimester (Neural tube defects)	
Pre-eclampsia Markers	
Placental Growth Factor (PLGF)	
SFlt-1	
SFlt-1: PLGF ratio	
Peptide I	
FSH, LH, AMH, Prolactin and Growth Hormone	
Peptide II	
PTH, ACTH and Calcitonin	
Tumour Markers	
AFP, CEA and hCG	

Edinburgh Peptide Hormones	
Services Available	
Pregnancy Testing	
Urinary hCG (Qualitative and Quantitative)	
Liver Fibrosis Markers	
Type III Procollagen Peptide (PIIINP)	
Enhanced Liver Fibrosis (ELF) Score	
FIB-4 Score	
Hyaluronic acid	
Tissue inhibitor of metalloproteinase I (TIMP-I)	

Guildford Peptides	
Tel:	+44 (0) 1483 571 122 ext. 3611
Email:	rsch.peptideeqa@nhs.net
Legal Entity:	Frimley Health NHS Foundation Trust
Services Available	
C-Peptide	
Gastrin	
Insulin	
Insulin-like Growth Factor 1	
Insulin-like Growth Factor Binding Protein-3	

Trace Elements	
Tel:	+44 (0) 1483 571 122 ext. 3611
Email:	rsc-tr.Guildford-EQA@nhs.net
Legal Entity:	Frimley Health NHS Foundation Trust
Services Available	
Lead, Cadmium, Manganese, Arsenic, Magnesium, Mercury, Zinc, Selenium, Thallium, Chromium and Cobalt in Whole Blood	
Mercury, Cadmium, Copper, Iron, Zinc, Chromium, Cobalt, Arsenic, Lead, Manganese, Nickel, Thallium and Selenium in Urine	
Zinc, Copper, Aluminium, Selenium, Chromium and Cobalt in Serum	

* not included in the current scope of accreditation

Clinical Chemistry

Trace Elements
Services Available (continued)
Aluminium in Water/Dialysis Fluid (Educational) *
Copper and Iron in Solid Matrices e.g. Liver (Educational) *

Genomics

Genomics (GenQA)	
Tel:	+44 (0) 131 242 6898
Email:	info@genqa.org
Legal Entity:	Oxford University Hospitals NHS Foundation Trust/NHS Lothian
Services Available	
Clinical Genetics & Genetic Counselling	
Cardiovascular disorders *	
Dysmorphology *	
Genetic counselling (Pilot)	
Monogenic disorders *	
Oncogenetic disorders *	
Genomic and Inherited Disorders	
Suitable for both cytogenomic and/or molecular testing	
Chromosome breakage syndromes	
Disorders of Sex Development (DSD)	
Hypotonic Infant	
Imprinting disorders	
Infertility	
Postnatal constitutional copy number variants (CNV) detection ¹	
Severe Developmental delay	
X-inactivation	
Genomic and Inherited Disorders	
Suitable for cytogenetic testing only	
Microdeletion syndromes *	

Genomics

Genomics (GenQA)
Services Available
Genomic and Inherited Disorders (continued)
Suitable for cytogenetic testing only
Postnatal karyotyping
Genomic and Inherited Disorders
Suitable for molecular testing only
Ataxia, including Hereditary Spastic Paraplegia (HSP)
Calcium disorders (Pilot)
Cardiac disorders
Charcot Marie Tooth disease and related sensory and motor neuropathies
Cystic fibrosis and CFTR-related disorders
Epilepsy disorders
Eye disorders
Familial Colorectal Cancer and Polyposis
Familial Endocrine tumour predisposition disorders
Familial Hypercholesterolaemia
Fragile X syndrome and FMR1-related disorders
Gastrohepatology disorders
Hereditary breast and ovarian cancer disorders (HBOC)
Huntington disease and DRPLA
Inborn Errors of Metabolism
Linkage analysis
Mitochondrial disease
Muscular dystrophies
Neurodegenerative disorders
Neurofibromatosis and rasopathies
Primary Immunodeficiency disorders (PID)
Renal disorders
Respiratory disorders
Skeletal Dysplasias

*Not within the current scope of accreditation

¹ Provided in collaboration with EMQN

² Provided in collaboration with UKNEQAS LI

³ Provided in collaboration with UK NEQAS Microbiology

Genomics

Genomics (GenQA)
Services Available
Haematological Neoplasms
Acute Lymphoblastic Leukaemia (ALL)
Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status ²
Chronic Lymphocytic Leukaemia (CLL) TP53 analysis ²
Haematological Technical FISH
Lymphoma
Lymphoma Technical NGS (Pilot)
Myeloid disorders
Myeloma
Molecular Newborn Screening
Molecular testing for cystic fibrosis (CF)
Molecular testing for Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)
Molecular testing for Severe Combined Immunodeficiency (SCID) (Pilot)
Molecular Pathology
BRCA testing for ovarian and prostate cancer - somatic ¹
BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline ¹
BRCA testing in prostate cancer – cfDNA ¹ (Pilot)
Breast cancer (PIK3CA testing) (Pilot)
Breast cancer - Tumour expression profiling (Pilot)
Central Nervous System (CNS) tumours
Colorectal cancer - core
Colorectal cancer - Extended MMR

Genomics (GenQA)
Services Available
Molecular Pathology (continued)
Colorectal cancer - mismatch repair (MMR)
Gastrointestinal Stromal Tumours (GIST)
Lung cancer - circulating free (cf) DNA in lung cancer ^{1*}
Lung cancer - comprehensive
Lung cancer - core
Lung cancer - EGFR
Lung cancer - fusions
Melanoma
Microsatellite Instability (MSI)
Molecular Tissue identification
Neuroblastoma (Pilot)
NTRK fusions
Renal tumours (Pilot)
Sarcoma
Thyroid cancer (Pilot)
Molecular Pathology
Individual Competency Assessment, educational only
Tumour content and cellularity of the tissue samples
Pharmacogenetics
Aminoglycoside Induced deafness
Prediction of 5-Fluorouracil toxicity (DPYD)
Prediction of Thiopurine toxicity (TPMT) (Pilot)
Preimplantation Genetic Testing (PGT)
PGT for aneuploidies
PGT for blastomere FISH (Stages 1 and 2)
PGT for monogenic disorders (Stage 1)
PGT for monogenic disorders (Stage 2)
PGT for structural rearrangements

*Not within the current scope of accreditation

¹ Provided in collaboration with EMQN

² Provided in collaboration with UKNEQAS LI

³ Provided in collaboration with UK NEQAS Microbiology

Genomics

Genomics (GenQA)
Services Available
Reproductive Genetics
Abnormal ultrasound with follow up testing (Pilot)
Maternal cell contamination (MCC) and fetal sexing
Non-invasive prenatal testing (NIPT) for aneuploidies ^{1*}
Non-invasive prenatal testing (NIPT) for common microdeletions *
Non-invasive prenatal testing (NIPT) for sexing ^{1*}
Pregnancy loss (Molecular methods and G-banding)
Prenatal constitutional copy number variant (CNV) detection
Prenatal karyotyping
Rapid prenatal testing for common aneuploidies
Sample Handling
DNA extraction from formalin-fixed paraffin embedded (FFPE) tissue
DNA extraction from fresh frozen (FF) tissue *
DNA extraction from saliva *
DNA extraction from venous blood
DNA quantification *
Technical – Next Generation Sequencing (NGS)
Next Generation Sequencing (NGS) germline ^{1*}
Next Generation Sequencing (NGS) somatic - tumour testing only ^{1*}
Next Generation Sequencing (NGS) somatic - tumour with germline subtraction analysis ^{1*}

Genomics (GenQA)
Services Available
Variant Classification & Interpretation
Pathogenicity of haematological neoplasm variants (Pilot)
Pathogenicity of somatic sequence variants (Pilot)
Variant Classification & Interpretation
Individual Competency Assessment, educational only
BRCA and HRR gene variant classification
Variant Classification & Interpretation
Nomenclature assessment suitable for cytogenomic interpretation
ISCN Accuracy (Pilot)
Variant Classification & Interpretation
Suitable for both molecular and cytogenomic interpretation
Exome Sequencing Data Interpretation
Pathogenicity of germline postnatal copy number variants (CNV) (Pilot)
Pathogenicity of prenatal copy number variants (CNV) (Pilot)
Variant validation
Variant Classification & Interpretation
Suitable for molecular interpretation
Pathogenicity of germline sequence variants (Classification only)
Pathogenicity of germline sequence variants (Classification & Interpretation)
Pathogenicity of RNA splicing variants (Pilot)
Viral Sequencing
SARS-CoV-2 sequencing (Pilot) ³



*Not within the current scope of accreditation

¹ Provided in collaboration with EMQN

² Provided in collaboration with UKNEQAS LI

³ Provided in collaboration with UK NEQAS Microbiology

Haematology

Blood Coagulation	
Tel:	+44 (0) 114 267 3300
Email:	neqas@coageqa.org.uk
Legal Entity:	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Screening Tests	
Activated Partial Thromboplastin Time (APTT)	
D-Dimer	
Fibrinogen Evaluation (Clauss Method)	
Heparin Assay (HA) - Anti-Xa	
Heparin Dosage Assessment (HDA) by APTT	
Prothrombin Time (PT)/INR (Venous/Capillary Methods)	
Prothrombin Time for Diagnosis (PT/Diagnostic) (PTD)	
Thrombin Time (TT)	
Assays	
Activated Protein C Resistance Assay	
Antithrombin Antigen and Activity Assays	
Factor II, V, VII VIII, IX, X, XI, XII Assays	
Plasminogen Assay	
Protein C Antigen and Activity Assay	
Protein S Activity Assay	
Protein S Total and Free Antigen Assay	
Von Willebrand Factor Antigen: Assay	
VWF:CB (Collagen-Binding) Assay	
VWF:RCo (Activity) Assay	
Other Programmes	
ADAMTS13 Assays	
DOAC Assays	
Emicizumab Assays	
FIX Treatment Monitoring	
FVIII Treatment Monitoring	
Genetics of Heritable Bleeding and Thrombotic Disorders	
HIT Screening/Assays	

Blood Coagulation	
Services Available	
Other Programmes	
Homocysteine Assays	
Lupus Anticoagulant Screening/Assay	
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	
Quantitative Factor VIII Inhibitor	
Point of Care Testing (POCT)	
Activated Clotting Time (ACT)	
INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II; Xprecia Stride; istat; LumiraDx	
POCT D-Dimer	
Thromboelastometry and Thromboelastography	

Blood Transfusion Laboratory Practice (BTLP)	
Tel:	+44 (0) 1923 587111
Email:	btlp@ukneqas.org.uk
Legal Entity:	West Hertfordshire Teaching Hospitals NHS Trust
Services Available	
ABO Titration (ABOT)	
ABO Titration	
A ₁ Typing	
Direct Antiglobulin Testing (DAT)	
Detection of Cells Coated with C3d	
Detection of Cells Coated with IgG	
Fetomaternal Haemorrhage (FMH)	
FMH Quantification	
FMH Screening	
Point of Care D Typing (POCTD)	
RhD Typing	
Pre-Transfusion Testing (PTT)	
ABO & D Grouping	
Antibody Identification	

* not included in the current scope of accreditation

Haematology

Blood Transfusion Laboratory Practice (BTLP)	
Services Available	
Pre-Transfusion Testing (PTT) (continued)	
Antibody Screening	
Crossmatching	
Rh and K Phenotyping	
Antenatal Antibody Titration (ANT) (Pilot)	
Red Cell Antibody Titration	
Extended Red Cell Phenotyping (ERP) (Pilot)	
Various Blood Group Antigen Phenotyping	
Red Cell Genotyping (RCG) (Pilot)	
Genotyping and Predicted Red Cell Phenotype for Various Blood Groups	
Educational	
Training, Assessment and Competency Tool (TACT)	

Haematology	
Services Available	
Haemoglobinopathy (continued)	
Sickle Screening only	
Morphology Related	
Blood Films for Morphology	
Blood Parasite Screening and Identification (Haematology)	
Cytochemistry: Haemosiderin Staining	
Digital Blood Film Morphology for CPD *	
Manual WBC Differential Count	
Rapid Diagnostic Tests for Malaria (Haematology)	
Red Cell Enzymopathies	
G6PD Screen and Assay	
Pyruvate Kinase Assay (Pilot) *	

Haematology	
Tel:	+44 (0)1923 587111
Email:	haem@ukneqas.org
Legal Entity:	West Hertfordshire Hospitals NHS Trust
Services Available	
Automated Counting & Related	
Automated Differential Leucocyte Count	
ESR	
Full Blood Count (FBC)	
Haemoglobin only	
Infectious Mononucleosis	
Plasma Viscosity	
Reticulocyte Count	
Haemoglobinopathy	
Abnormal Haemoglobins	
DNA Diagnostics for Haemoglobinopathies	
Liquid Newborn Haemoglobinopathy Screening	
Newborn Sickle Screening	

Leucocyte Immunophenotyping	
Tel:	+44 (0) 114 267 3600
Email:	admin@ukneqasli.co.uk
Legal Entity:	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Flow Cytometry	
CD34+ Stem Cell Enumeration	
Cerebrospinal Fluid (CSF) Immunophenotyping *	
Competency Assessment and Instrument Validation Panel for Immune Monitoring	
Haematological Malignancy Bone Marrow Aspirate Assessment *	
Immune Monitoring	
Leukaemia Diagnostic Interpretation (Part 2)	
Leukaemia Immunophenotyping (Part 1)	
Low Level Leucocyte Enumeration	
Measurable Residual Disease for ALL by Flow Cytometry	

* not included in the current scope of accreditation

Haematology

Leucocyte Immunophenotyping	
Services Available	
Flow Cytometry (continued)	
Measurable Residual Disease for AML by Flow Cytometry *	
Measurable Residual Disease for CLL by Flow Cytometry *	
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry *	
Paroxysmal Nocturnal Haemoglobinuria	
Molecular	
Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels *	
BCR::ABL1 and AML Translocation Identification	
BCR::ABL1 Kinase Domain Variant (Mutation) Status	
BCR::ABL1 Major Quantification	
BCR::ABL1 Minor Quantification *	
BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	
Chronic Lymphocytic Leukaemia Gene Panels *	
FLT3 Mutation Status	
IG/TCR Clonality Status	
JAK2 p.Val617Phe (V617F) Mutation Status	
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	
Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia *	
Measurable Residual Disease for AML by Molecular Methods *	
Myeloproliferative Neoplasm Gene Panels *	
NPM1 Mutation Status	
Paediatric Acute Leukaemia Translocations	
Post-Stem Cell Transplant Chimerism Monitoring	

Immunology

Histocompatibility and Immunogenetics	
Tel:	+44 (0) 1443 622 185
Email:	handi@ukneqas.org.uk
Legal Entity:	Velindre University NHS Trust
Services Available	
Crossmatching by Flow Cytometry	
Cytotoxic Crossmatching	
DNA HLA Typing at 1st Field Resolution	
DNA HLA Typing to 2nd or 3rd Field Resolution	
Educational Cross Match	
Educational Interpretive Clinical Scenarios	
Educational Scheme	
HFE Typing	
HLA Antibody Detection	
HLA Antibody Specificity Analysis	
HLA Genotyping for Coeliac and other HLA associated diseases	
HLA Phenotyping	
HLA-B*57:01 Typing for Drug Hypersensitivity	
HLA-B27 Testing	
HPA Antibody Detection/Specification	
HPA Genotyping	
Interpretative: HFE Genotype and Hereditary Haemochromatosis	
Interpretive HLA Genotype	
KIR Genotyping	



Immunology

Immunology, Immunochemistry & Allergy (IIA)	
Tel:	+44 (0) 114 271 5715
Email:	immunology@ukneqas.org.uk
Legal Entity:	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Allergy and Immunodeficiency	
Allergen Component Testing	
Allergen Specific IgE	
Antibody to Fungal & Related Antigens	
IgG Subclasses	
Specific Microbial Antibodies (Tetanus/HiB/Pneumococcal antibodies)	
Total IgE	
Tryptase	
Autoimmunity	
Acetylcholine Receptor Antibodies	
ANCA/GBM Antibodies	
Antibodies to Nuclear and Related Antigens	
Bullous Dermatitis Antibodies	
Coeliac Disease Antibodies	
Diabetic Markers	
Ganglioside Antibodies	
General Autoimmune Serology (CCP/RF/TPO/TRAB/AMA/LKM/SMA/GPC)	
Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB	
Myelin Associated Glycoprotein IgM Antibodies (MAG)	
Myositis Associated Antibodies	
Nuclear Antibodies (ANA/DNA/ENA)	
Paraneoplastic Antibodies	
Phospholipase A2 Receptor Antibodies	

Immunology, Immunochemistry & Allergy (IIA)	
Services Available	
Autoimmunity (continued)	
Phospholipid Antibodies	
SARS-CoV-2 Antibody Detection	
Digital	
Cryoproteins *	
Digital ANA *	
Interpretative EQA (iEQA) *	
Immunochemistry	
Alkaline Phosphatase (ALP) Isoenzymes	
Alpha 1 Antitrypsin and Phenotype Identification	
C1 Esterase Inhibitor and Functional Complement Assays	
C-Reactive Protein (CRP)	
CSF Haem Pigments	
CSF IgG Oligoclonal Bands	
CSF Proteins and Biochemistry	
CSF β 2 Transferrin/Beta Trace Protein	
Interleukin-6 (IL-6) *	
Point of Care CRP	
Procalcitonin	
Ultrasensitive C-Reactive Protein	
β 2 Microglobulin	
Oncology	
Monoclonal Protein Identification	
Prostate Specific Antigen (Total and Free PSA)	
Tumour Markers (CA125/CA199/CA153/NSE/CgA *)	
Ultrasensitive PSA	

* not included in the current scope of accreditation

Medical Microbiology

Microbiology	
Tel:	+44 (0) 208 905 9890
Email:	organiser@ukneqasmicro.org.uk
Legal Entity:	UK Health Security Agency
Services Available	
Bacteriology	
AAFB Microscopy	
Antimicrobial Susceptibility	
Carbapenemase Producing Organisms (CPO)*	
Clostridioides Difficile (prev. Clostridium Difficile)	
Community Medicine	
Faecal Pathogens	
General Bacteriology	
General Bacteriology & Antimicrobial Susceptibility	
Genital Pathogens	
MRSA Screening	
Mycobacteria Culture	
Syphilis Serology	
Urinary Antigens	
Molecular	
C. Trachomatis and N. Gonorrhoeae	
CMV DNA Quantification	
EBV DNA Quantification	
HBV DNA Quantification	
Hepatitis C RNA Detection	
HIV 1 RNA Quantification	
Molecular Detection Mycobacteria	
Molecular Detection of HPV	
Molecular Detection of Respiratory Viruses	
Molecular Detection of SARS-CoV-2	
Molecular Detection of Viruses in CSF	
Viral Gastroenteritis (also suitable for antigen testing)	

Microbiology	
Mycology	
Antifungal Susceptibility	
Cryptococcal Antigen Detection	
Fungal Biomarkers	
Mycology	
Virology	
Anti-HBs Detection	
Blood Borne Viruses	
Blood Donor Screen	
Diagnostic Serology: Hepatitis Screen	
Hepatitis B Serology	
Hepatitis C Serology	
Hepatitis E Detection *	
HIV Point of Care	
HIV Serology	
Immunity Screen	
Measles and Mumps IgG Serology	
Parvovirus B19 and Rubella Serology	
Respiratory Rapid: RSV	
Rubella IgG Serology	
SARS-CoV2 Point of Care *	

Parasitology	
Tel:	+44 (0) 203 908 1371
Email:	parasite@ukneqas.org.uk
Legal Entity:	UK Health Security Agency
Services Available	
Blood Parasitology	
Faecal Parasitology	
Malaria Rapid	
Molecular Detection of Faecal Parasites	
Molecular Diagnosis of Malaria	
Parasite Serology	
Teaching for Blood and Faecal Parasites	
Toxoplasma Serology	

Point of Care Testing (POCT)

UK NEQAS monitors, supports and educates non-laboratory trained operators to improve the quality of diagnostic test performance and interpretation of results. We offer external quality assessment (EQA) for POCT in the following areas:

Services Available	Provided By
Activated Clotting Time (ACT)	UK NEQAS Blood Coagulation
B-Type Natriuretic Peptide (BNP)	UK NEQAS Cardiac Markers
Cardiac Troponin I	UK NEQAS Cardiac Markers
Cardiac Troponin T	UK NEQAS Cardiac Markers
CKMB	UK NEQAS Cardiac Markers
Clinical Chemistry	UK NEQAS Birmingham Quality
C-Reactive Protein (CRP)	UK NEQAS Immunology, Immunochemistry & Allergy (IIA)
Cryptococcal Antigen	UK NEQAS Microbiology
D-Dimer	UK NEQAS Blood Coagulation
D-Typing	UK NEQAS Blood Transfusion Laboratory Practice (BTLP)
Fungal Biomarkers	UK NEQAS Microbiology
Glycated Haemoglobins	UK NEQAS Birmingham Quality
Haemoglobin Only	UK NEQAS Haematology
HIV	UK NEQAS Microbiology
INR Testing (CoaguChek XS series, CoaguChek Pro II, Xprecia Stride, i-STAT, LumiraDx)	UK NEQAS Blood Coagulation
Malaria Rapid	UK NEQAS Parasitology
Molecular Detection of Respiratory Viruses	UK NEQAS Microbiology
Myoglobin	UK NEQAS Cardiac Markers
NT-pro BNP	UK NEQAS Cardiac Markers
Pregnancy Testing	UK NEQAS Edinburgh Peptide Hormones
Respiratory Rapid: RSV	UK NEQAS Microbiology
Thromboelastometry and Thromboelastography	UK NEQAS Blood Coagulation
Urinary Antigens	UK NEQAS Microbiology
Urine Dipsticks	UK NEQAS Birmingham Quality
Viral Gastroenteritis (also suitable for antigen testing)	UK NEQAS Microbiology

Pre- and Post-Analytical Quality Monitoring Service (PrepQ)

The control of pre- and post-analytical errors in diagnostic testing is recognised as a major contributor to the improvement in laboratory quality. Although the cause of many errors may be outside the laboratory, they waste resources and impair effective patient care.

The UK NEQAS response

UK NEQAS has developed a web-based pre- and post-analytical quality monitoring service (PrepQ), as an external comparison tool. This tool gives the laboratory the opportunity to collate and monitor the incidence of errors beyond the analytical phase against their peers.

Registering to PrepQ

Registration to the PrepQ monitoring service is flexible. It can be done by department, discipline, laboratory, hospital, or network, depending upon the individual participant's service arrangements. Regular monitoring periods allow the laboratory to return data at a frequency convenient to them against as many of the key assurance indicators as they are able to collect.

PrepQ is a web-based service

The PrepQ service is offered on a secure on-line basis through the UK NEQAS Results and Reports service. Participants submit the number of quality failures compared to the number of opportunities for failure in a given time period. Performance evaluation is reported using sigma metrics, allowing immediate benchmarking with the laboratory's peers.

Pre- and post-analytical case scenarios

PrepQ includes scenarios in pre- and post-analytical monitoring up to 4 times a year. The scenarios reflect current concerns in laboratory errors that originate outside the analytical phase. The responses are requested in the form of multiple-choice questions and brief free-text comments, and the results are reported with a short expert commentary that can be used within the laboratory for education and service development.

Is PrepQ available in your area?

Yes. PrepQ is an international programme and is available to any participant in any UK NEQAS service.

PrepQ covers a wide range of disciplines, including Blood Sciences (Haematology, Clinical Chemistry, and Immunology), Microbiology and other specialised areas.

Schedule of Exercises

PrepQ offers a regular schedule of exercises, with generous data submission windows and rapid feedback to laboratories.

The current schedule allows data submission and reports on a monthly basis. Participants are alerted by email to opening and close dates.

Interested?

If you would like to know more about the PrepQ service, which is provided as a benefit of UK NEQAS membership, and how it could help your laboratory, please contact us on this email: prepq@ukneqas.org.uk or call us on 0114 2611689.

Programme Index

#	Page	A	Page
1st Trimester (Down's syndrome and Trisomies T13 and T18)	6	Aminoglycoside Induced deafness	8
1st Trimester (Down's syndrome using dried blood spots) (Pilot)	6	ANCA/GBM Antibodies	13
2nd Trimester (Down's syndrome)	6	Andrology: Semen Analysis (Sperm Motility, Concentration & Morphology)	15
2nd Trimester (Neural tube defects)	6	Antenatal Antibody Titration (ANT) (Pilot)	11
β 2 Microglobulin	13	Antibiotic Assays	5
A	Page	Antibodies (MAG)	13
A ₁ Typing	10	Antibodies to Nuclear and Related Antigens	13
AAFB Microscopy	14	Antibody Identification	10
Abnormal Haemoglobins	11	Antibody Screening	11
Abnormal ultrasound with follow up testing (Pilot)	9	Antibody to Fungal & Related Antigens	13
ABO & D Grouping	10	Antifungal Assays	5
ABO Titration	10	Antifungal Susceptibility	14
ABO Titration (ABOT)	10	Anti-HBs Detection	14
ACE*	5	Antimicrobial Susceptibility	14
Acetylcholine Receptor Antibodies	13	Antithrombin Antigen and Activity Assays	10
Activated Clotting Time (ACT)	10, 16	Assays	10
Activated Partial Thromboplastin Time (APTT)	10	Ataxia, including Hereditary Spastic Paraplegia (HSP)	7
Activated Protein C Resistance Assay	10	Autoimmunity	13
Acute and Chronic Kidney Disease (Creatinine, Cystatin C, eGFR and AKI)	5	Automated Counting & Related	11
Acute Lymphoblastic Leukaemia (ALL)	8	Automated Differential Leucocyte Count	11
Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels*	12	B	Page
ADAMTS13 Assays	10	Bacteriology	14
AFP, CEA and hCG	6	BCR::ABL1 and AML Translocation Identification	12
Alimentary Tract Pathology (GIST)	4	BCR::ABL1 Kinase Domain Variant (Mutation) Status	12
Alkaline Phosphatase (ALP) Isoenzymes	13	BCR::ABL1 Major Quantification	12
Allergen Component Testing	13	BCR::ABL1 Minor Quantification*	12
Allergen Specific IgE	13	Bile Acids*	5
Allergy and Immunodeficiency	13	Birmingham Quality	5
Alpha 1 Antitrypsin and Phenotype Identification	13	Blood Borne Viruses	14
Aluminium in Water/Dialysis Fluid (Educational)*	7	Blood Coagulation	10
		Blood Donor Screen	14

Programme Index

B (continued)	Page	C	Page
Blood Films for Morphology	11	Cardiac Markers Schemes (Point of Care)	6
Blood Parasite Screening and Identification (Haematology)	11	Cardiac Troponin I	16
Blood Parasitology	14	Cardiac Troponin I, Cardiac Troponin T, CKMB, Myoglobin, BNP ⁱ , NT-proBNP	6
Blood Transfusion Laboratory Practice (BTLP)	10, 11	Cardiac Troponin T	16
Bone Marrow Trepine Biopsy (BMT)	4	Cardiovascular disorders*	7
BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	12	CD34+ Stem Cell Enumeration	11
BRCA and HRR gene variant classification	9	Cellular Pathology	4, 5
BRCA testing for ovarian and prostate cancer - somatic ¹	8	Cellular Pathology Technique	4
BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline ¹	8	Central Nervous System (CNS) tumours	8
BRCA testing in prostate cancer - cfDNA ¹ (Pilot)	8	Cerebrospinal Fluid (CSF) Immunophenotyping*	11
Breast Cancer - Tumour expression profiling (Pilot)	8	Charcot Marie Tooth disease and related sensory and motor neuropathies	7
Breast cancer (<i>PIK3CA</i> testing) (Pilot)	8	Chromosome breakage syndromes	7
Breast HER2 ISH (Interpretive and Technical)	5	Chronic Lymphocytic Leukaemia (CLL)	8
Breast Pathology (HER2 IHC)	4	Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status ²	8
Breast Pathology (Hormonal Receptors ER & PR)	4	Chronic Lymphocytic Leukaemia (CLL) <i>TP53</i> analysis ²	8
Breast Pathology (Hormonal Receptors ER only)	4	Chronic Lymphocytic Leukaemia Gene Panels*	12
B-Type Natriuretic Peptide (BNP)	6, 16	CKMB	16
Bullous Dermatitis Antibodies	13	Clinical Chemistry	5, 6, 7, 16
C	Page	Clinical Genetics & Genetic Counselling	7
C. Trachomatis and N. Gonorrhoeae	14	Clostridioides Difficile (prev. Clostridium Difficile)	14
C1 Esterase Inhibitor and Functional Complement Assays	13	CMV DNA Quantification	14
Calcium disorders (Pilot)	7	Coeliac Disease Antibodies	13
Carbapenemase Producing Organisms (CPO)*	14	Colorectal cancer - core	8
Cardiac disorders	7	Colorectal cancer - Extended MMR	8
Cardiac Markers	6	Colorectal cancer - mismatch repair (MMR)	8
Cardiac Markers Schemes (Laboratory)	6	Community Medicine	14
		Competency Assessment and Instrument Validation Panel for Immune Monitoring	11

Programme Index

C (continued)	Page	D	Page
Copper and Iron in Solid Matrices e.g. Liver (Educational)*	7	Direct Antiglobulin Testing (DAT)	10
C-Peptide	6	Direct Immunofluorescence (DIF)	4
C-Reactive Protein (CRP)	13, 16	Disorders of Sex Development (DSD)	7
Crossmatching	11	DNA Diagnostics for Haemoglobinopathies	11
Crossmatching by Flow Cytometry	12	DNA extraction from formalin-fixed paraffin embedded (FFPE) tissue	9
Cryoproteins *	13	DNA extraction from fresh frozen (FF) tissue*	9
Cryptococcal Antigen	16	DNA extraction from saliva*	9
Cryptococcal Antigen Detection	14	DNA extraction from venous blood	9
CSF Haem Pigments	13	DNA HLA Typing at 1st Field Resolution	12
CSF IgG Oligoclonal Bands	13	DNA HLA Typing to 2nd or 3rd Field Resolution	12
CSF Proteins and Biochemistry	13	DNA quantification*	9
CSF β 2 Transferrin/Beta Trace Protein	13	DOAC Assays	10
Cystic fibrosis and CFTR-related disorders	7	D-Typing	16
Cytochemistry: Haemosiderin Staining	11	Dysmorphology*	7
Cytopathology	4	E	Page
Cytotoxic Crossmatching	12	EBV DNA Quantification	14
D	Page	Edinburgh Peptide Hormones	6
D-Dimer	10, 16	Educational	11
Detection of Cells Coated with C3d	10	Educational Cross Match	12
Detection of Cells Coated with IgG	10	Educational Interpretive Clinical Scenarios	12
Diabetic Markers	13	Educational Scheme	12
Diagnostic Cytopathology	4	Embryology: Embryo Morphology, Time Lapse Annotation	15
Diagnostic Cytopathology Cell Block (Pilot)	4	Emicizumab Assays	10
Diagnostic Serology: Hepatitis Screen	14	Enhanced Liver Fibrosis (ELF) Score	6
Digital	13	Epilepsy disorders	7
Digital ANA *	13	Erythropoietin	5
Digital Blood Film Morphology for CPD *	11	ESR	11
Digital Diagnostic Ultrastructural Pathology (Pilot)	4	Exome Sequencing Data Interpretation	9
Digital Interpretative Diagnostic Cytopathology	4	Extended Red Cell Phenotyping (ERP) (Pilot)	11
Digital Interpretative Synovial Fluid Crystals (Pilot)	4	Eye disorders	7
Digital Interpretive Web Based Schemes	4		
Digital Pathology (Pilot)	4		

Programme Index

F	Page	G	Page
Factor II, V, VII VIII, IX, X, XI, XII Assays	10	General Autoimmune Serology (CCP/ RF/TPO/TRAB/AMA/LKM/SMA/GPC)	13
Faecal Haemoglobin	5	General Bacteriology	14
Faecal Markers	5	General Bacteriology & Antimicrobial Susceptibility	14
Faecal Pancreatic Elastase	5	General Pathology	4
Faecal Parasitology	14	Genetic counselling (Pilot)	7
Faecal Pathogens	14	Genetics of Heritable Bleeding and Thrombotic Disorders	10
Familial Colorectal Cancer and Polyposis	7	Genital Pathogens	14
Familial Endocrine tumour predisposition disorders	7	Genomic and Inherited Disorders	7
Familial Hypercholesterolaemia	7	Suitable for both cytogenomic and/or molecular testing	
Fetomaternal Haemorrhage (FMH)	10	Genomic and Inherited Disorders	7
FIB-4 Score	6	Suitable for cytogenetic testing only	
Fibrinogen Evaluation (Clauss Method)	10	Genomic and Inherited Disorders	7
FIX Treatment Monitoring	10	Suitable for molecular testing only	
Flow Cytometry	11, 12	Genomics	7, 8, 9
FLT3 Mutation Status	12	Genotyping and Predicted Red Cell Phenotype for Various Blood Groups	11
Fluids	5	GenQA	7, 8, 9
FMH Quantification	10	Glycated Haemoglobins	5, 16
FMH Screening	10	Guildford Peptides	6
Fragile X syndrome and FMR1-related disorders	7	H	Page
Frozen Section (Companion Scheme to Specialist Techniques and Neuropathology)	4	Haematinics	5
Fructosamine	5	Haematological Malignancy Bone Marrow Aspirate Assessment*	11
FSH, LH, AMH, Prolactin and Growth Hormone	6	Haematological Neoplasms	8
Full Blood Count (FBC)	11	Haematological Technical FISH	8
Fungal Biomarkers	14, 16	Haematology	10, 11, 12
FVIII Treatment Monitoring	10	Haemoglobin only	11, 16
G	Page	Haemoglobinopathy	11
G6PD Screen and Assay	11	HBV DNA Quantification	14
Ganglioside Antibodies	13	Head and Neck Pathology	4
Gastric HER2 IHC	4	Head and Neck Pathology (Oral, ENT & Combined)*	4
Gastrin	6	Heparin Assay (HA) - Anti-Xa	10
Gastrohepatology disorders	7	Heparin Dosage Assessment (HDA) by APTT	10
Gastrointestinal Stromal Tumours (GIST)	8		

Programme Index

H (continued)	Page	I	Page
Hepatitis B Serology	14	Immune Monitoring	11
Hepatitis C RNA Detection	14	Immunity Screen	14
Hepatitis C Serology	14	Immunochemistry	13
Hepatitis E Detection*	14	Immunocytochemistry	4, 5
Hereditary breast and ovarian cancer disorders (HBOC)	7	Immunocytochemistry and In-Situ Hybridisation	4, 5
HFE Typing	12	Immunology	12, 13, 14
High Sensitivity Cardiac Troponin I (Pilot)	6	Immunology, Immunochemistry & Allergy (IIA)	13, 14
High-risk HPV in Head & Neck Pathology (Pilot)	5	Immunosuppressants	5
Histocompatibility and Immunogenetics	12, 13	Imprinting disorders	7
HIT Screening/Assays	10	Inborn Errors of Metabolism	7
HIV	16	Infectious Mononucleosis	11
HIV 1 RNA Quantification	14	Infertility	7
HIV Point of Care	14	INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II; Xprecia Stride; istat; LumiraDx	10, 16
HIV Serology	14	In-Situ Hybridisation	5
HLA Antibody Detection	12	Insulin	6
HLA Antibody Specificity Analysis	12	Insulin-like Growth Factor 1	6
HLA Genotyping for Coeliac and other HLA associated diseases	12	Insulin-like Growth Factor Binding Protein-3	6
HLA Phenotyping	12	Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB	13
HLA-B*57:01 Typing for Drug Hypersensitivity	12	Interleukin-6 (IL-6)*	13
HLA-B27 Testing	12	Interpretative Comments in Clinical Chemistry	5
Holotranscobalamin	5	Interpretative EQA (iEQA) *	13
Homocysteine Assays	10	Interpretative: HFE Genotype and Hereditary Haemochromatosis	13
HPA Antibody Detection/Specification	12	Interpretive HLA Genotype	13
HPA Genotyping	12	Intrinsic Factor Antibodies	5
hs Cardiac Troponin I, hs Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	6	ISCN Accuracy (Pilot)	9
Huntington disease and DRPLA	7	J	Page
Hyaluronic acid	6	JAK2 p.Val617Phe (V617F) Mutation Status	12
Hypotonic Infant	7		
I	Page		
IG/TCR Clonality Status	12		
IgG Subclasses	13		

Programme Index

K	Page	M	Page
Ki-67 in Breast Cancer (Pilot)	5	Measurable Residual Disease for ALL by Flow Cytometry	11
KIR Genotyping	12	Measurable Residual Disease for AML by Flow Cytometry*	12
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	12	Measurable Residual Disease for AML by Molecular Methods *	12
L	Page	Measurable Residual Disease for CLL by Flow Cytometry*	12
Lead, Cadmium, Manganese, Arsenic, Magnesium, Mercury, Zinc, Selenium, Thallium, Chromium and Cobalt in Whole Blood	6	Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry*	12
Leucocyte Immunophenotyping	11, 12	Medical Microbiology	14, 15
Leukaemia Diagnostic Interpretation (Part 2)	11	Mega Block (Companion Scheme to Specialist Techniques and Neuropathology)	4
Leukaemia Immunophenotyping (Part 1)	11	Melanoma	8
Linkage analysis	7	Mercury, Cadmium, Copper, Iron, Zinc, Chromium, Cobalt, Arsenic, Lead, Manganese, Nickel, Thallium and Selenium in Urine	6
Lipid Investigations	5	Microbiology	14
Liquid Newborn Haemoglobinopathy Screening	11	Microdeletion syndromes*	7
Liver Fibrosis Markers	6	Microsatellite Instability (MSI)	8
Low Level Leucocyte Enumeration	11	Mismatch Repair (MMR) Proteins	4
Lung cancer - Circulating free (cf) DNA in lung cancer ^{1*}	8	Mitochondrial disease	7
Lung cancer - comprehensive	8	MK-4 at endogenous concentrations in human serum	5
Lung cancer - core	8	MK-7 at endogenous concentrations in human serum	5
Lung cancer - EGFR	8	Mohs' Procedure	4
Lung cancer - fusions	8	Molecular	12, 14
Lupus Anticoagulant Screening/Assay	10	Molecular Detection Mycobacteria	14
Lymphoid Pathology	4	Molecular Detection of Faecal Parasites	14
Lymphoma	8	Molecular Detection of HPV	14
Lymphoma Technical NGS (Pilot)	8	Molecular Detection of Respiratory Viruses	14, 16
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia*	12	Molecular Detection of SARS-CoV-2	14
M	Page	Molecular Detection of Viruses in CSF	14
Malaria Rapid	14, 16	Molecular Diagnosis of Malaria	14
Manual WBC Differential Count	11		
Maternal cell contamination (MCC) and fetal sexing	9		
Maternal Serum Screening	6		
Measles and Mumps IgG Serology	14		

Programme Index

M (continued)	Page	N	Page
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	10	Next Generation Sequencing (NGS) germline ^{1*}	9
Molecular Newborn Screening	8	Next Generation Sequencing (NGS) somatic - tumour testing only ^{1*}	9
Molecular Pathology	8	Next Generation Sequencing (NGS) somatic - tumour with germline subtraction analysis ^{1*}	9
Molecular Pathology Individual Competency Assessment, educational only	8	Non-invasive prenatal testing (NIPT) for aneuploidies ^{1*}	9
Molecular testing for cystic fibrosis (CF)	8	Non-invasive prenatal testing (NIPT) for common microdeletions*	9
Molecular testing for Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	8	Non-invasive prenatal testing (NIPT) for sexing ^{1*}	9
Molecular testing for Severe Combined Immunodeficiency (SCID)*	8	Non-Small Cell Lung Cancer (NSCLC) ALK IHC	4
Molecular Tissue identification	8	Non-Small Cell Lung Cancer (NSCLC) ALK ISH (Pilot)	5
Monitoring (TDM)	5	Non-Small Cell Lung Cancer (NSCLC) PD-L1 IHC (Pilot)	4
Monoclonal Protein Identification	13	Non-Small Cell Lung Cancer (NSCLC) ROS1 FISH (Pilot)	5
Monogenic disorders*	7	Non-Small Cell Lung Cancer (NSCLC) ROS1 IHC (Pilot)	4
Morphology Related	11	NPM1 Mutation Status	12
MRSA Screening	14	NT-pro BNP	16
Muscle Histochemistry	4	NTRK fusions	8
Muscular dystrophies	7	Nuclear Antibodies (ANA/DNA/ENA)	13
Mycobacteria Culture	14	O	Page
Mycology	14	Oncogenetic disorders*	7
Myelin Associated Glycoprotein IgM	13	Oncology	13
Myeloid disorders	8	Other Programmes (BTLP)	10
Myeloma	8	P	Page
Myeloproliferative Neoplasm Gene Panels*	12	p16 in Head & Neck Pathology (Pilot)	5
Myoglobin	16	Paediatric Acute Leukaemia Translocations	12
Myositis Associated Antibodies	13	Paediatric Bilirubin	5
N	Page	Paraneoplastic Antibodies	13
Neuroblastoma (Pilot)	8	Parasite Serology	14
Neurodegenerative disorders	7	Parasitology	14
Neurofibromatosis and rasopathies	7	Paroxysmal Nocturnal Haemoglobinuria	12
Neuropathology	4, 5	Parvovirus B19 and Rubella Serology	14
Neuropathology Interpretative EQA Scheme*	5		
Newborn Screening	5		
Newborn Sickle Screening	11		

Programme Index

P (continued)	Page	P	Page
Pathogenicity of germline postnatal copy number variants (CNV) (Pilot)	9	Pre and Post-Analytical Quality Monitoring Service (PrepQ)	17
Pathogenicity of germline sequence variants (Classification & Interpretation)	9	Prediction of 5-Fluorouracil toxicity (DPYD)	8
Pathogenicity of germline sequence variants (Classification only)	9	Prediction of Thiopurine toxicity (TPMT) (Pilot)	8
Pathogenicity of haematological neoplasm variants (Pilot)	9	Pre-eclampsia Markers	6
Pathogenicity of prenatal copy number variants (CNV) (Pilot)	9	Pregnancy loss (Molecular methods and G-banding)	9
Pathogenicity of RNA splicing variants (Pilot)	9	Pregnancy Testing	6, 16
Pathogenicity of somatic sequence variants (Pilot)	9	Preimplantation Genetic Testing (PGT)	8
Peptide I	6	Prenatal constitutional copy number variant (CNV) detection	9
Peptide II	6	Prenatal karyotyping	9
PGT for aneuploidies	8	Pre-Transfusion Testing (PTT)	10, 11
PGT for blastomere FISH	8	Primary Immunodeficiency disorders (PID)	7
PGT for monogenic disorders	8	Procalcitonin	13
PGT for structural rearrangements	8	Prostate Specific Antigen (Total and Free PSA)	13
Pharmacogenetics	8	Protein C Antigen and Activity Assay	10
Phospholipase A2 Receptor Antibodies (PLA2R)	13	Protein S Activity Assay	10
Phospholipid Antibodies	13	Protein S Total and Free Antigen Assay	10
Placental Growth Factor (PLGF)	6	Prothrombin Time (PT)/INR (Venous/ Capillary Methods)	10
Plasma Viscosity	11	Prothrombin Time for Diagnosis (PT/ Diagnostic) (PTD)	10
Plasminogen Assay	10	PTH, ACTH and Calcitonin	6
POCT D-Dimer	10	Pyruvate Kinase Assay (pilot) *	11
Point of Care Testing (POCT)	10	Q	Page
Point of Care CRP	13	Quantitative Amino Acids	5
Point of Care D Typing (POCTD)	10	Quantitative Factor VIII Inhibitor	10
Point of Care Testing (POCT)	16	R	Page
Postnatal constitutional copy number variants (CNV) detection ¹	7	Rapid Diagnostic Tests for Malaria (Haematology)	11
Postnatal karyotyping	7	Rapid prenatal testing for common aneuploidies	9
Post-Stem Cell Transplant Chimerism Monitoring	12	Red Cell Antibody Titration	11
		Red Cell Enzymopathies	11
		Red Cell Genotyping (RCG) (Pilot)	11

Programme Index

R (continued)	Page	T	Page
Renal Biopsy Pathology	4	Thrombin Time (TT)	10
Renal disorders	7	Thromboelastometry and Thromboelastography	10, 16
Renal tumours (Pilot)	8	Thyroglobulin	5
Reproductive Genetics	9	Thyroid cancer (Pilot)	8
Reproductive Science	15	Thyroid Hormones	5
Respiratory disorders	7	Tissue Diagnostics	4
Respiratory Rapid: RSV	14, 16	Tissue inhibitor of metalloproteinase I (TIMP-I)	6
Reticulocyte Count	11	Total IgE	13
Rh and K Phenotyping	11	Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)	5
RhD Typing	10	Toxoplasma Serology	14
Rubella IgG Serology	14	Trace Elements	6, 7
S	Page	Training, Assessment and Competency Tool (TACT)	11
Sample Handling	9	Transmission Electron Microscopy (TEM)	4
Sarcoma	8	Triple Negative Breast Cancer (TNBC) PD-L1 IHC (Pilot)	4
SARS-CoV-2 Antibody Detection	13	Tryptase	13
SARS-CoV2 Point of Care*	14	Tumour content and cellularity of the tissue samples	8
SARS-CoV-2 sequencing (Pilot) ³	9	Tumour Markers	6
Screening Tests	10	Tumour Markers (CA125/CA199/CA153/ NSE/CgA*)	13
Serum Indices (HIL)	5	Type III Procollagen Peptide (PIIINP)	6
Severe Developmental delay	7	U	Page
SFlt-1	6	Ultrasensitive C-Reactive Protein	13
SFlt-1: PLGF ratio	6	Ultrasensitive PSA	13
Sickle Screening only	11	Urinary Antigens	14, 16
Skeletal Dysplasias	7	Urinary Catecholamines & Metabolites	5
Slide Based Schemes	4	Urinary hCG (Qualitative and Quantitative)	6
Specialist Techniques	4	Urine Chemistries	5
Specific Microbial Antibodies (Tetanus/ HiB/Pneumococcal antibodies)	13	Urine Dipsticks	5, 16
Specific Proteins	5	V	Page
Steroid Hormones	5	Variant Classification & Interpretation	9
Sweat Testing	5	Variant Classification & Interpretation	9
Syphilis Serology	14	Individual Competency Assessment, educational only	
T	Page		
Teaching for Blood and Faecal Parasites	14		
Technical – Next Generation Sequencing (NGS)	9		

Programme Index

V (continued)	Page
Variant Classification & Interpretation	9
Nomenclature assessment suitable for cytogenomic interpretation	
Variant Classification & Interpretation	9
Suitable for both molecular and cytogenomic interpretation	
Variant Classification & Interpretation	9
Suitable for molecular interpretation	
Variant validation	9
Various Blood Group Antigen Phenotyping	11
Viral Gastroenteritis (also suitable for antigen testing)	14, 16
Viral Sequencing	9
Virology	14
Vitamin Assays (Carotene, Vitamin A & E)	5
Vitamin D	5
Vitamin K1 at endogenous concentrations in human serum	5
Vitamin K1, 2, 3-epoxide at endogenous concentrations in human serum	5
Von Willebrand Factor Antigen: Assay	10
VWF:CB (Collagen-Binding) Assay	10
VWF:RCo (Activity) Assay	10
W, X, Y, Z	Page
Web Based Schemes (CPT)	4
X-inactivation	7
Zinc, Copper, Aluminium, Selenium, Chromium and Cobalt in Serum	6

Participating Countries

UK NEQAS is the **world leading** provider of clinical laboratory External Quality Assessment (EQA)/ Proficiency Testing (PT) programmes. Below, and continued on page 19, is a list of countries currently participating in UK NEQAS EQA/PT.

A	Cote d'Ivoire	Guernsey
Afganistan	Croatia	Guinea
Albania	Cuba	Guyana
Algeria	Curacao	H
Angola	Cyprus	Haiti
Argentina	Czech Republic	Honduras
Armenia	D	Hong Kong
Aruba	Denmark	Hungary
Australia	Dominican Republic	I
Austria	E	Iceland
Azerbaijan	Ecuador	India
B	Egypt	Indonesia
Bangladesh	El Salvador	Iran
Barbados	Equatorial Guinea	Iraq
Belarus	Estonia	Ireland
Belgium	Ethiopia	Isle of Man
Benin	F	Israel
Bermuda	Falkland Islands	Italy
Bolivia	Faroe Islands	J
Bosnia and Herzegovina	Fiji	Jamaica
Botswana	Finland	Japan
Brazil	France	Jordan
Bulgaria	French Guiana	K
Burkina Faso	French Polynesia	Kazakhstan
C	G	Kenya
Cambodia	Gambia	Kingdom of Bahrain
Cameroon	Georgia	Kosovo
Canada	Germany	Kuwait
Central Africa Republic	Ghana	Kyrgyzstan
Chile	Gibraltar	L
China	Greece	Lao PDR
Colombia	Greenland	Latvia
Congo, Democratic Republic	Guadeloupe	Lebanon
Costa Rica	Guatemala	Lesotho

Participating Countries

L (continued)	O	South Korea
Liberia	Oman	Spain
Liechtenstein	P	Sri Lanka
Lithuania	Pakistan	Sudan
Luxembourg	Palestine	Swaziland
M	Panama	Sweden
Macau	Papua New Guinea	Switzerland
Macedonia	Paraguay	T
Madagascar	Peru	Taiwan
Malawi	Philippines	Tajikistan
Malaysia	Poland	Tanzania
Mali	Portugal	Tchad
Malta	Q	Thailand
Martinique	Qatar	Togo
Mauritania	R	Tunisia
Mauritius	Republic of Ireland	Turkey
Mexico	Republic of Korea	Turkmenistan
Monaco	Republic of Macedonia	U
Mongolia	Republic of Moldova	Uganda
Montenegro	Reunion	United Kingdom
Morocco	Romania	Ukraine
Mozambique	Russia	United Arab Emirates
Myanmar	Rwanda	Uruguay
N	S	USA
Namibia	Saudi Arabia	Uzbekistan
Nepal	Scotland	V
Netherlands	Senegal	Venezuela
New Caledonia	Serbia	Vietnam
New Zealand	Sierra Leone	W, X, Y, Z
Nicaragua	Singapore	Yemen
Niger	Sint Maarten	Zambia
Nigeria	Slovak Republic	Zimbabwe
Northern Ireland	Slovenia	
Norway	South Africa	

UK NEQAS Centre Contacts

UK NEQAS Centre	Telephone Number	Email Address
Birmingham Quality	+44 (0) 121 414 7300	birminghamquality@uhb.nhs.uk
Blood Coagulation	+44 (0) 114 267 3300	neqas@coageqa.org.uk
Blood Transfusion Laboratory Practice (BTLP)	+44 (0) 1923 587111	btlp@ukneqas.org.uk
Cardiac Markers	+44 (0) 141 440 2888	info@ukneqas-cm.org.uk
Cellular Pathology Technique	+44 (0) 191 816 1030	cpt@ukneqas.org.uk
Edinburgh Peptide Hormones	+44 (0) 131 242 6885	ukneqas@ed.ac.uk
GenQA	+44 (0) 131 242 6898	info@genqa.org
Guildford Peptide Hormones	+44 (0) 1483 571 122 ext. 3611	rsch.peptideeqa@nhs.net
Haematology	+44 (0) 1923 587111	haem@ukneqas.org
Head & Neck Pathology	+44 (0) 121 371 5723	neckpath@ukneqas.org.uk
Histocompatibility & Immunogenetics	+44 (0) 1443 622 185	handi@ukneqas.org.uk
Immunocytochemistry & In-Situ Hybridisation (ICC&ISH)	+44 (0) 208 187 9174	info@ukneqasiccish.org
Immunology, Immunochemistry & Allergy (IIA)	+44 (0) 114 271 5715	immunology@ukneqas.org.uk
Leucocyte Immunophenotyping (LI)	+44 (0) 114 267 3600	admin@ukneqasli.co.uk
Microbiology	+44 (0) 208 905 9890	organiser@ukneqasmicro.org.uk
Neuropathology	+44 (0) 1865 234 904	neuropath@ukneqas.org.uk
Parasitology	+44 (0) 203 908 1371	parasite@ukneqas.org.uk
Reproductive Science	+44 (0) 161 276 6437	repscience@ukneqas.org.uk
Trace Elements	+44 (0) 1483 571 122 ext. 3611	rsc-tr.Guildford-EQA@nhs.net

UK NEQAS Central Office

PO Box 401

Sheffield

South Yorkshire

S5 7YZ.

T: +44 (0) 114 2611689

E: centraloffice@ukneqas.org

W: www.ukneqas.org.uk